daxor.com (DXR) EV/EBITDA Multiple

Daxor Corporation (DXR) minimizes third-party procurement by maintaining precise in-house assembly. Its monopoly status in the diagnostic automation segment allows Daxor Corporation (DXR) to avoid dumping, a fact confirmed by the company's pricing evolution with a metric of 7.03. Financial stability is based on regular sales of ancillary products, which create a predictable cash flow within this niche sector.

DXR (Daxor Corp) Business Value to Operating Income Before Depreciation history from 11/23/2025 to 11/12/2026

DXR (daxor.com): analytical breakdowns and indicator data

- current price and projected stock value:

Stock Price Daxor|DXR - Analyst Median Target

- market capitalization details:

Market Capitalization Daxor Corporation|DXR - Real Price to Acquire Entire Company

- issuer book value statistics:

Accounting Value per Share Daxor|DXR - Accounting Value of Company|Market Value to Book Value Ratio daxor.com|DXR - Cumulative Company Assets

- debt level and financial liquidity data:

- net income and valuation multiples indicators:

DXR - Net Profit|Expected Profit Daxor Corporation|DXR - Price to Earnings Ratio|Projected Price to Earnings Daxor|DXR - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Daxor Corporation|DXR - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Daxor|DXR - Net earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months daxor.com|DXR - Earnings growth in current year|Earnings growth forecast for next year Daxor Corporation

Fundamental company valuation:Daxor Corp. DXR

This indicator compares Enterprise Value (EV) to operating profit before depreciation and amortization, allowing for an assessment of the company's ability to service debt and taxes regardless of its capital structure. By analyzing the current EV/EBITDA ratio of Daxor Corporation (DXR), an investor determines the market value of assets relative to their yield, which is critically important for Daxor Corporation given its monopoly dominance in the precision volemia analysis market.

Analysis of competing companies

EV/EBITDA Multiple ABT (Abbott Laboratories Inc.)|Total Company Value to Operating Income Before Depreciation Ratio Thermo Scientific (TMO)|GE HealthCare - EV/EBITDA Multiple|mt.com (MTD) - Enterprise Value to EBITDA Ratio|WAT (Waters) - Enterprise Value to EBITDA Ratio|Bio-Techne Corp - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bruker Corp.|Enterprise Value to EBITDA Ratio Brooks Automation (AZTA)|EV/EBITDA Multiple VREX|SMLR - Company Value to EBITDA|EV/EBITDA Multiple BFLY (Butterfly Network)|MLAB: Enterprise Value to Operating Income Before Depreciation|Quantum-Si Corp - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Nano-X Imaging Ltd NNOX|QTRX: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio 908devices.com|CV (CapsoVision, Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple MaxCyte Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Rapid Micro Biosystems (RPID)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SEER (Seer Bio)|Hyperfine, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation FONR|Spectral AI, Inc. - EV/EBITDA Multiple|Company Value to EBITDA Organovo Holdings|Aclarion Corp (ACON) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Multiple Akoya Biosciences, Inc. AKYA|Enterprise Value to EBITDA Ratio THMO|EV/EBITDA Multiple Talis Biomedical Corp|EV/EBITDA Multiple TTOO